Study S001038

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07073053
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 60
Start: 2025-10-01
Primary completion: 2028-07-31
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Conditions: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
Interventions: DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.5 mg
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

change of Time-in-range (%) [From enrollment to the end of treatment at 24 weeks]
change of HbA1c [From enrollment to the end of treatment at 24 weeks]
change of Flow-Mediated Dilatation (FMD) [From enrollment to the end of treatment at 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.